Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. тройно комбинирано лечение) като допълнение към диета и упражнения при пациенти, недостатъчно контролирани за тяхното максимално переносимой дозата на метформина и сульфонилмочевины. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - Множествена Склероза, Рецидивно-Ремиттирующее - Иммунодепрессанты селективен иммунодепрессанты - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

България - български - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland b.v. - milbemycin oxime; praziquantel - таблетка - 5.0 mg; 50.0 mg/таблетка - кучета

България - български - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland b.v. - milbemycin oxime; praziquantel - таблетка - 12.0 mg; 30.0 mg/таблетка - котки

България - български - БАБХ (Българска агенция по безопасност на храните)

alf - milbemycin oxime; praziquantel - таблетка - 12.5 mg; 125.0 mg/таблетка - кучета

България - български - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland b.v. - milbemycin oxime; praziquantel - таблетка - 16.0 mg; 40.0 mg/таблетка - котки

България - български - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland b.v. - Мильбемицин оксим, Празиквантел - таблетка - 20,0 mg, 200,0 mg/mg - кучета

България - български - БАБХ (Българска агенция по безопасност на храните)

alfasan nederland b.v. - milbemycin oxime; praziquantel - таблетка - 4.0 mg; 10.0 mg/таблетка - котки

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - диметил фумарат - multiple sclerosis, relapsing-remitting; multiple sclerosis - Имуносупресори - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).